Media Summary: E. David Crawford, MD, discusses the concept of disruptive technologies—developments which displace established technology ... Dr. E. David Crawford presented "The "Who's" of Dr. M. Scott Lucia presented "The "Who's" of
The Use Of Genomic Markers And Prostate Biopsy Decisions - Detailed Analysis & Overview
E. David Crawford, MD, discusses the concept of disruptive technologies—developments which displace established technology ... Dr. E. David Crawford presented "The "Who's" of Dr. M. Scott Lucia presented "The "Who's" of John W. Davis, MD, discusses the benefits and limitations of utilizing Eric A. Klein, MD, chairman, Glickman Urological & Kidney Institute, and staff member, Taussig Cancer Institute, Cleveland Clinic, ... Dr. Gerald L. Andriole, Jr. presented "The "Who's" of
Matthew R. Cooperberg, MD, MPH, addresses updates in E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of ... When a patient takes the Oncotype DX test, Donate to PCRI: For more information, visit 0:22 M. Scott Lucia, MD, University of Colorado, Denver, Aurora, Colorado, discusses if there are
Dr. David Lee talks about using new genetic/ When men are found to have an elevated PSA or are at risk for Bertrand Tombal, MD, PhD, discusses active surveillance as the standard of care for a high-risk localized disease and the ...
![Targeted Diagnosis in Prostate Cancer with Dr. Todd Morgan [EP-121]](https://i.ytimg.com/vi/_o91c62aLFA/mqdefault.jpg)
